Analysis of Expression and Regulation of AKR1C2 in HPV-Positive and -Negative Oropharyngeal Squamous Cell Carcinoma
Cancers · 27.08.2024 · 16 (17) · 2976
DOI: 10.3390/cancers16172976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 27.08.2024. Verfasst von Maria Ziogas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, 50937 Cologne, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jean-Uhrmacher-Foundation.
Abstract (Originalsprache)
Head and Neck Squamous Cell Carcinoma (HNSCC), particularly Oropharyngeal Squamous Cell Carcinoma (OPSCC), is a major global health challenge due to its increasing incidence and high mortality rate. This study investigates the role of aldo-keto reductase 1C2 (AKR1C2) in OPSCC, focusing on its expression, correlation with Human Papillomavirus (HPV) status, oxidative stress status, and clinical outcomes, with an emphasis on sex-specific differences. We analyzed AKR1C2 expression using immunohistochemistry in formalin-fixed, paraffin-embedded tissue samples from 51 OPSCC patients. Additionally, we performed RT-qPCR in cultured HPV16-E6*I and HPV16-E6 overexpressing HEK293 cell lines (p53WT). Statistical analyses were performed to assess the correlation between AKR1C2 expression and patient data. Our results indicate a significant association between increased AKR1C2 expression and higher AJCC classification (p = 0.009) as well as positive HPV status (p = 0.008). Prognostic implications of AKR1C2 varied by sex, whereby female patients with high AKR1C2 expression had better overall survival, whereas male patients exhibited poorer outcomes. Additionally, AKR1C2 expression was linked to HPV status, suggesting a potential HPV-specific regulatory mechanism. These findings underscore the complex interplay among AKR1C2, HPV, and patient sex, highlighting the need for personalized treatment strategies for OPSCC. Targeted inhibition of AKR1C2, considering sex-specific differences, may enhance therapeutic outcomes. Future research should investigate these mechanisms to enhance treatment efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, 50937 Cologne, Germany.
- Molecular Head and Neck Oncology, Translational Research in Infectious Diseases and Oncology (TRIO) Research Building, University Hospital of Cologne, 50937 Cologne, Germany.
- Department of Internal Medicine, Faculty of Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, 50937 Cologne, Germany.
- Department of Neurology, University Hospital of Cologne, 50924 Cologne, Germany.
- Institute for Pathology, University Hospital of Cologne, 50937 Cologne, Germany.
ORCID-Profile: Maria Ziogas, Nora Wuerdemann, Elena Gross, Jens Peter Klussmann
Förderung
- Jean-Uhrmacher-Foundation
Zitieren
APA
Ziogas, M., Siefer, O., Wuerdemann, N., Balaji, H., Gross, E., Drebber, U., Klussmann, J. P., & Huebbers, C. U. (2024). Analysis of Expression and Regulation of AKR1C2 in HPV-Positive and -Negative Oropharyngeal Squamous Cell Carcinoma. Cancers, 16(17), 2976. https://doi.org/10.3390/cancers16172976
Vancouver
Ziogas M, Siefer O, Wuerdemann N, Balaji H, Gross E, Drebber U, et al. Analysis of Expression and Regulation of AKR1C2 in HPV-Positive and -Negative Oropharyngeal Squamous Cell Carcinoma. Cancers. 2024;16(17):2976. doi:10.3390/cancers16172976
BibTeX
@article{Ziogas2024,
author = {Ziogas, Maria and Siefer, Oliver and Wuerdemann, Nora and Balaji, Harini and Gross, Elena and Drebber, Uta and Klussmann, Jens Peter and Huebbers, Christian U},
title = {Analysis of Expression and Regulation of AKR1C2 in HPV-Positive and -Negative Oropharyngeal Squamous Cell Carcinoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {2976},
doi = {10.3390/cancers16172976}
}
EUVIMED